Clinical trial · Observational
Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform
NCT06868927CI-TRIAL-00105752TARGET-RCCrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aims to provide an accurate strategy to guide the decision making relying on tumor biopsies using standard histology, immunohistochemistry (IHC), spatial transcriptomics, genomics combined with Magnetic Resonance Imaging (MRI) and radiomics. Moreover, the investigators will explore potential markers indicative of response to systemic agents or ablative therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Tumors | Kidney Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- accuracy of multiparametric preoperative MRI
- timeFrame
- At final pathological assessment , at least 1 month after surgery
- description
- Detection of "Unfavourable outcome" is defined as the presence of at least one of the following pathological characteristics: * High grade tumor (G3 or G4) * Not-organ confined disease (pT3 and or pT4 and/or LNI) * Sarcomatoid features
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Presence of a renal mass up to 4 cm * Adult \> 18 years * Candidate to renal surgery * Informed consent signed Exclusion Criteria: * Contraindication for MRI
References
Publications (0)
Data not yet available
No reference posted for this study.